GSK PLC closed 25.31% below its 52-week high of £18.24, which the company reached on May 16th.

GSK has been found guilty of bringing discredit on the pharma industry after a complainant flagged “a shocking error” in the prescribing information for the JAK inhibitor Omjjara. A person who ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. The U.K.’s Medicines and Healthcare products Regulatory Agency ...

Pharma with 3,615 puts trading, or 1.6x expected. Most active are May-25 30 puts and Aug-25 35 puts, with total ...

April 15 (Reuters) - British pharmaceutical giant GSK (GSK.L), opens new tab has not met required ethical and regulatory standards in the marketing and prescription information for its Omjjara ...

BNP Paribas Exane analyst Peter Verdult initiated coverage of GSK (GSK) with a Neutral rating and $35.25 price target Stay Ahead of the Market: ...

GSK GSK and Pfizer PFE announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the expanded use of their ...

The Food and Drug Administration on Tuesday approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker ...

LONDON, March 25 (Reuters) - GSK (GSK.L), opens new tab said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its best-selling shingles ...

GSK plc GSK announced that the FDA has approved its oral antibiotic gepotidacin for treating uncomplicated urinary tract infections (uUTIs) in female adults and adolescents. A commercial launch ...

At its 52-week peak on 16 May 2024, the GSK share price hit 1,823.5p, but it’s been mostly downhill ever since. Last week, as stock markets crashed, GSK shares collapsed to 1,242.5p on Wednesday 9 ...